Advances in BABE

In pharmacology, bioavailability (BA) is a subcategory of ingestion and is the part of a managed measurement of unaltered medication that achieves the systemic flow, one of the important pharmacokinetic properties of medications. Bioavailability is one of the crucial apparatuses in pharmacokinetics, as bioavailability must be considered when computing doses for non-intravenous courses of organization.

  • Application of Nano technology to improve bioavailabilty
  • Innovative strategies
  • Isotope drug studies in man
  • Bioequivalence Criteria
  • Risks in bioequivalence assessment
  • Requirement to determine the active principle
  • SUPAC: scale-up and for post-approval changes
  • Relevance of bioequivalence in approving generic copies of drug products
  • Electronic regulatory submission and review
  • Drug application regulatory compliance
  • New drug quality assessment
  • Highly variable and low permeable drugs
  • Complex generics

Related Conference of Advances in BABE

June 08-09, 2018

7th International conference on Pharmaceutical Auditing

Baltimore, Maryland, USA
June 27-28, 2018

4th International Conference on Drug Discovery, Designing and Development

Vancouver, British Columbia, Canada
August 20-21, 2018

9th Asian Biologics and Biosimilars Congress

Tokyo, Japan
October 18-19, 2018

18th World Pharma Congress

Warsaw, Poland
September 18-19, 2018

6th European Biopharma Congress

Amsterdam, Netherlands

Advances in BABE Conference Speakers

Recommended Sessions

Related Journals

Are you interested in